Company: CERO
Filing Date: 2025-11-28
Form Type: DEF 14A
Source: 0001213900-25-115783
Chunk: 35

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-28
Form: DEF 14A
Chunk 35
---
1625 per share of the Series E Preferred Stock. Such shares would constitute approximately 10.1% of the then -CommonStock after the issuance of such shares. Because the conversion price of the Series E Preferred Stock 18

may be adjusted, the number of shares that will actually be issued may be more or less than such number of shares, as further described under “Potential Adjustments” above. The ownership interest of the existing stockholders (other than the October 2025 Investors) would be correspondingly reduced. The number of shares of Common Stock described above does not give effect to (i) the potential future issuance of additional shares of Common Stock due to potential future anti -dilutionadjustments on the Series E Preferred Stock, (ii) the potential future issuance of shares of Common Stock pursuant to the Permitted Equity Lines (as defined in the October 2025 Securities Purchase Agreement), (iii) the potential future issuance of shares of Common Stock pursuant to other outstanding options and warrants, or (iv) any other potential future issuances of Common Stock. The sale into the public market of these shares also could materially and adversely affect the market price of the Common Stock. If this proposal is approved, the issuance of the Common Stock could have an anti -takeovereffect because such issuance would make it more difficult for, or discourage an attempt by, a party to obtain control of the Company by tender offer or other means. The issuance of the Common Stock will increase the number of shares entitled to vote, increase the number of votes required to approve a change of control of the Company, and dilute the interest of a party attempting to obtain control of the Company. The Board does not have any current knowledge of any effort by any third party to accumulate the Company’s securities or obtain control of the Company by any means. If this proposal is not approved, the October 2025 Investors will not be able to vote or convert their shares of Series E Preferred Stock. Under the October 2025 Securities Purchase Agreement, the consent of the October 2025 Investors is required in order for the Company to be permitted to issue securities in capital raising transactions at an offering price below the current conversion price of the Series E Preferred Stock unless this proposal is approved. If this proposal is not approved, the October 2025 Investors may withhold such consent, preventing the Company from conducting such an offering. The Company may be unable to obtain alternative financing, which would prevent the Company from having sufficient resources to fund its operations. As a result, the